1) Conjugate the PNAM polymer with DFO;
2) Develop libraries of DF@DL and DF@OR via PISA technique with 10% (w/w free PNAM) of DFO-PNAM and different percentage of APDs initial feeding;
3) Prepare a library of DF@DLOR nanoplatforms composed by DF@DL and DF@OR;
4) Evaluate NPs' physicochemical and morphological features as well as their storage stability;
5) Evaluate the APDs' kinetic release of the most promising PNN NPs under physiological and oxidative conditions;
6) Measure the interaction of the DF@DLOR with nasal mucous;
7) Evaluate the toxicological and pharmacological profile of the DF@DLOR in dopaminergic neuronal (SH-SY5Y), epithelial (RPMI 2650), microgial (HMC3) and hepatic (HepG2) cells;
8) Study the pharmacological performance of DF@DLOR in a human Substantia Nigra Brain-Chip. |